MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

NCT05020249 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-03-18

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.

Conditions

Interventions

DRUG

bimekizumab

Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.

OTHER

Placebo

Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-27
Primary Completion
2022-09-05
Completion
2022-09-06

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05020249 on ClinicalTrials.gov